Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

JAMA dermatology·2026

Same author

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Chemically induced skin tumors arise from long-lived stem cells of the upper hair follicle.

Science (New York, N.Y.)·2026

Same author

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Data Harmonization for Collaborative Research Among Australian and US Registries: A Case Study in Medullary Thyroid Cancer (MTC).

World journal of surgery·2026

Same author

Intraoperative Parathyroid Hormone Monitoring During Parathyroidectomy in Severe Secondary Hyperparathyroidism due to Kidney Failure.

World journal of surgery·2026

Search research articles

Related Experiment Video

Updated: Sep 11, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic

Justin Bauzon¹, Guillermo Ponce de Leon-Ballesteros^2,3, Eddy Lincango⁴

¹Department of Endocrine Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Thyroid : Official Journal of the American Thyroid Association

|August 13, 2025

Summary

Neoadjuvant multikinase inhibitors (MKIs) may improve surgical resection rates in advanced differentiated thyroid cancer (DTC). Further prospective studies are needed to confirm these findings due to low-quality evidence.

Keywords:

differentiated thyroid cancer locally advanced thyroid cancer multikinase inhibitors tyrosine kinase inhibitors

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Sep 11, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Area of Science:

Oncology
Endocrinology
Surgical Oncology

Background:

Multikinase inhibitors (MKIs) are established for managing advanced thyroid cancers.
Neoadjuvant MKIs have been suggested for locally advanced differentiated thyroid cancer (DTC).

Conclusions:

Neoadjuvant MKIs show potential for improving resection rates in locally advanced DTC.
The current evidence quality is low, necessitating further prospective research.
Confirming the benefits of neoadjuvant MKIs requires robust clinical trials.